After a hit to the head or rapid whiplash, whether from a car crash, athletic event or other accident, millions of Americans develop traumatic brain injuries (TBIs) each year. TBIs can range from mild concussions, causing only a headache or temporary blurred vision, to much more severe injuries, causing seizures, confusion, memory and attention problems, muscle weakness, or coma for many months. These symptoms, whether mild or more severe, are generally caused by damaged brain cells.
Most physicians rely on CT scans and patients’ symptoms to determine whether to send them home and have them resume their usual activities or take extra precautions. However, CT scans can only detect bleeding in the brain, not damage to brain cells, which can happen without bleeding. Now, a new blood test from researchers at Johns Hopkins University could help emergency room doctors quickly diagnose traumatic brain injury and determine its severity. The team state that the findings could help identify patients who might benefit from extra therapy or experimental treatments and that compared to other proteins that have been measured in traumatic brain injury, BDNF does a much better job of predicting outcomes.
Previous studies show that a typical situation is that someone comes to the emergency department with a suspected TBI, recieves a CT scan, and if the scan shows no bleeding, is sent home. However, these patients go home and continue having headaches, difficulty concentrating and memory problems, and they can’t figure out why they are having these symptoms after doctors told them everything was fine.
The team wanted to discern if a blood test could better predict which patients would have ongoing brain injury-related problems, to provide better treatment for them. So the current study measured the levels of three proteins that they suspected play a role in brain cell activity in more than 300 patients with a TBI and 150 patients without brain injuries. Then, they followed those with a TBI for the next six months.
The data findings show that levels of one protein, called brain-derived neurotrophic factor (BDNF), taken within 24 hours of someone’s head injury, could predict the severity of a TBI and how a patient would fare. While healthy people averaged 60 nanograms per milliliter of BDNF in their bloodstreams, patients with brain injuries had less than one-third of that amount, averaging less than 20 nanograms per milliliter, and those with the most severe TBIs had even lower levels, around 4 nanograms per milliliter. Moreover, patients with high levels of BDNF had mostly recovered from their injuries six months later. But in patients with the lowest levels of BDNF, symptoms still lingered at follow-up. The results suggest that a test for BDNF levels, administered in the emergency room, could help stratify patients.
The researchers state that the advantage of being able to predict prognosis early on is that patients can be advised on what to do, recommend whether they need to take time off work or school, and decide whether they need to follow-up with a rehab doctor or neurologist. They go on to add that in addition, it could help decide which patients to enroll in clinical trials for new drugs or therapies targeting severe TBIs.
For the future the lab would like to follow up with more research on why, at a molecular level, brain injuries lower levels of BDNF in the blood and whether things known to increase BDNF levels, including exercise and omega-3 fatty acids, could help treat TBIs. They also plan to investigate whether changes in BDNF levels over time can be a proxy for recovery and if they could be used to gauge the effectiveness of an intervention. The group have already started collecting data for those prospective studies.
The team surmise that they looked at that very first blood sample obtained within 24 hours of an injury. However they note that for BDNF to be used as a surrogate outcome, they will have to see what happens to BDNF blood levels down the line, at one, three or six months after the injury.
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.